This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by von Wasielewski, R. Articles by Georgii, A. Search for Related Content PubMed PubMed Citation Articles by von Wasielewski, R. Articles by Georgii, A.

American Journal of Pathology, Vol 150, 793-803, Copyright © 1997 by American Society for Investigative Pathology

REGULAR ARTICLES

Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group

R von Wasielewski, M Werner, R Fischer, ML Hansmann, K Hubner, D Hasenclever, J Franklin, M Sextro, V Diehl and A Georgii
Pathologische Institute of the Medizinische, Hochschule Hannover, Germany.

There is wide consensus that lymphocyte predominance Hodgkin's disease (LPHD) represents a distinct clinicopathological entity of B-cell origin. However, inconsistent results of immunophenotyping studies and low confirmation rates among multi-center trials pose the question of whether LPHD really expresses heterogeneous marker profiles or whether it represents a mixture of morphologically similar entities. Among 2,836 cases reviewed by the German Hodgkin Study Group, immunophenotyping was performed on 1) cases classified or confirmed as LPHD by the reference panel (n = 104) or 2) cases not confirmed as LPHD but classified as classical HD (cHD) within the reference study trial (n = 104). In most cases, immunohistochemistry revealed a phenotype either LPHD-like (CD20+, CD15-, CD30-, CD45+) or cHD-like (CD15+, CD30+, CD20-, CD45-). In 27 cases, the immunophenotype was not fully conclusive. Additional markers for Epstein-Barr virus and CD57 and in situ hybridization for mRNA light chains allowed for a more clear-cut distinction between LPHD and cHD. However, in 25 of 104 cases, immunohistochemistry disproved the morphological diagnosis of LPHD of the panel experts, whereas 13 cases originally not confirmed as LPHD showed a LPHD-like immunopattern. Immunohistochemically confirmed LPHD cases showed a significantly better freedom from treatment failure (P = 0.033) than cHD; this was not observed in the original study classification based only on morphology (P > 0.05). Significantly better survival for LPHD cases improved from P = 0.047 (original study classification) to P = 0.0071 when classified by immunohistochemistry. Our results show that LPHD is a more immunohistochemical rather than a purely morphological diagnosis. Immunophenotyping of HD biopsies suspected of being LPHD is mandatory when a modified therapy protocol, that is, one different from those used in cHD, is discussed.

This article has been cited by other articles:

				L. Nogova, T. Rudiger, and A. Engert Biology, Clinical Course and Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 266 - 272. [Abstract] [Full Text] [PDF]

				C. Atayar, S. Poppema, T. Blokzijl, G. Harms, M. Boot, and A. van den Berg Expression of the T-Cell Transcription Factors, GATA-3 and T-bet, in the Neoplastic Cells of Hodgkin Lymphomas Am. J. Pathol., January 1, 2005; 166(1): 127 - 134. [Abstract] [Full Text] [PDF]

				L. Boudova, E. Torlakovic, J. Delabie, P. Reimer, B. Pfistner, S. Wiedenmann, V. Diehl, H.-K. Muller-Hermelink, and T. Rudiger Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma Blood, November 15, 2003; 102(10): 3753 - 3758. [Abstract] [Full Text] [PDF]

				A. Tzankov, J. Krugmann, F. Fend, M. Fischhofer, R. Greil, and S. Dirnhofer Prognostic Significance of CD20 Expression in Classical Hodgkin Lymphoma: A Clinicopathological Study of 119 Cases Clin. Cancer Res., April 1, 2003; 9(4): 1381 - 1386. [Abstract] [Full Text] [PDF]

				G. Z. Rassidakis, L. J. Medeiros, S. Viviani, V. Bonfante, G.-P. Nadali, T. P. Vassilakopoulos, O. Mesina, M. Herling, M. K. Angelopoulou, R. Giardini, et al. CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin's Disease: Associations With Presenting Features and Clinical Outcome J. Clin. Oncol., March 1, 2002; 20(5): 1278 - 1287. [Abstract] [Full Text] [PDF]

				S A Pileri, S Ascani, L Leoncini, E Sabattini, P L Zinzani, P P Piccaluga, A Pileri Jr, M Giunti, B Falini, G B Bolis, et al. Hodgkin's lymphoma: the pathologist's viewpoint J. Clin. Pathol., March 1, 2002; 55(3): 162 - 176. [Abstract] [Full Text] [PDF]

				M. L. Gulley Molecular Diagnosis of Epstein-Barr Virus-Related Diseases J. Mol. Diagn., February 1, 2001; 3(1): 1 - 10. [Abstract] [Full Text]

				H. Stein, T. Marafioti, H.-D. Foss, H. Laumen, M. Hummel, I. Anagnostopoulos, T. Wirth, G. Demel, and B. Falini Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription Blood, January 15, 2001; 97(2): 496 - 501. [Abstract] [Full Text] [PDF]

				N. L. Harris, H. Stein, S. E. Coupland, M. Hummel, R. D. Favera, L. Pasqualucci, and W. C. Chan New Approaches to Lymphoma Diagnosis Hematology, January 1, 2001; 2001(1): 194 - 220. [Abstract] [Full Text] [PDF]

				B. F. Skinnider, A. J. Elia, R. D. Gascoyne, L. H. Trumper, F. von Bonin, U. Kapp, B. Patterson, B. E. Snow, and T. W. Mak Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma Blood, January 1, 2001; 97(1): 250 - 255. [Abstract] [Full Text] [PDF]

				I. Anagnostopoulos, M.-L. Hansmann, K. Franssila, M. Harris, N. L. Harris, E. S. Jaffe, J. Han, J. M. van Krieken, S. Poppema, T. Marafioti, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes Blood, September 1, 2000; 96(5): 1889 - 1899. [Abstract] [Full Text] [PDF]

				R. von Wasielewski, S. Seth, J. Franklin, R. Fischer, K. Hubner, M. L. Hansmann, V. Diehl, and A. Georgii Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors Blood, February 15, 2000; 95(4): 1207 - 1213. [Abstract] [Full Text] [PDF]

				K. F. Izban, T. Wrone-Smith, E. D. Hsi, B. Schnitzer, M. E. Quevedo, and S. Alkan Characterization of the Interleukin-1ß-Converting Enzyme/Ced-3-Family Protease, Caspase-3/CPP32, in Hodgkin's Disease : Lack of Caspase-3 Expression in Nodular Lymphocyte Predominance Hodgkin's Disease Am. J. Pathol., May 1, 1999; 154(5): 1439 - 1447. [Abstract] [Full Text] [PDF]

				V. Diehl, M. Sextro, J. Franklin, M.-L. Hansmann, N. Harris, E. Jaffe, S. Poppema, M. Harris, K. Franssila, J. van Krieken, et al. Clinical Presentation, Course, and Prognostic Factors in Lymphocyte-Predominant Hodgkin's Disease and Lymphocyte-Rich Classical Hodgkin's Disease: Report From the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease J. Clin. Oncol., March 1, 1999; 17(3): 776 - 776. [Abstract] [Full Text] [PDF]